NCT02173639已完成1 期
Relative Oral Bioavailability of a Fixed Dose Combination Tablet of BI 1356 2.5 mg / Metformin 1000 mg, Compared With Single BI 1356 2.5 mg and Metformin 1000 mg Tablets Administered Together to Healthy Male and Female Subjects in an Open, Randomised, Single-dose, Two-way Crossover, Phase I Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 主要终点
- AUC0-72 h (area under the concentration-time curve of BI 1356 in plasma over the time interval from 0 to 72 h)
研究概览
简要总结
The objective was to assess the relative bioavailability of a pilot scale linagliptin 2.5 mg / metformin 1000 mg fixed dose combination (FDC) tablet in comparison with single tablets of linagliptin 2.5 mg and metformin 1000 mg administered together.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy males and females based upon a complete medical history, including the physical examination, vital signs (Blood Pressure, Pulse Rate), 12-lead Electrocardiogram, clinical laboratory tests
- •Age ≥18 and ≤ 55 years
- •BMI ≥18.5 and ≤29.9 kg/m2 (Body Mass Index)
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation
排除标准
- •Any finding of the medical examination deviating from normal and of clinical relevance. Repeated measurement of a systolic blood pressure greater than 140 mm Hg or a diastolic blood pressure greater than 90 mm Hg
- •Any evidence of a clinically relevant concomitant disease
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Surgery of the gastrointestinal tract (except appendectomy)
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
- •Intake of drugs within one month or less than 10 half-lives of the respective drug prior to first study drug administration and during the trial except if a relevant interaction can be ruled out
- •Participation in another trial with an investigational drug within two months prior to first study drug administration or during the trial
- •Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- •Inability to refrain from smoking on pharmacokinetic study days
- •Alcohol abuse (average consumption of more than 20 g/day in females and more than 30 g/day in males)
- •Drug abuse
- •Blood donation (more than 100 mL within four weeks prior to the start of study)
- •Excessive physical activities (within one week prior to administration or during the trial)
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of trial site
- •A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval > 450 ms)
- •A history of additional risk factors for Torsade de Pointes (TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
- •For female subjects:
- •Positive pregnancy test, pregnancy or planning to become pregnant during the study or within 2 months after study completion
- •No adequate contraception during the study and until 2 months after study completion, i.e. not any of the following: implants, injectables, combined oral contraceptives, IUD (intrauterine device), sexual abstinence for at least 1 month prior to enrolment, vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or surgical sterilisation (including hysterectomy). Females, who do not have a vasectomised partner, are not sexually abstinent or surgically sterile will be asked to use an additional barrier method (e.g. condom, diaphragm with spermicide)
- •Lactation
研究组 & 干预措施
BI 1356/metformin
Experimental
干预措施: BI 1356/metformin (Drug)
BI 1356 + Metformin
Experimental
干预措施: BI 1356 (Drug)
BI 1356 + Metformin
Experimental
干预措施: Metformin (Drug)
结局指标
主要结局
AUC0-72 h (area under the concentration-time curve of BI 1356 in plasma over the time interval from 0 to 72 h)
时间窗: up to 72 hours after administration
Cmax (maximum measured concentration of the analyte in plasma)
时间窗: up to 168 hours after administration
AUC0-∞ (area under the concentration-time curve of metformin in plasma over the time interval from 0 to infinity)
时间窗: up to 168 h after administration
次要结局
- Assessment of tolerability on a 4-point scale by investigator(14 days after last study drug administration)
- tmax (time from dosing to maximum concentration of the analyte in plasma)(up to 168 hours after administration)
- MRTpo (mean residence time of the analyte in the body after po administration)(up to 168 hours after administration)
- CL/F (apparent clearance of the analyte in the plasma after extravascular administration)(up to 168 hours after administration)
- Vz/F (apparent volume of distribution during the terminal phase λz of the analyte following an extravascular dose)(up to 168 hours after administration)
- Number of patients with adverse events(up to 11 weeks)
- AUC0-24 h (area under the concentration-time curve of BI 1356 and metformin in plasma over the time interval from 0 to the 24 h)(up to 24 h after administration)
- AUC0-tz (area under the concentration-time curve of BI 1356 and metformin in plasma over the time interval from 0 to the time of the last quantifiable data point)(up to 168 h after administration)
- AUC0-∞ (area under the concentration time curve of BI 1356 in plasma over the time interval from 0 extrapolated to infinity)(up to 168 h after administration)
- λz (terminal elimination rate constant of the analyte in plasma)(up to 168 hours after administration)
- t1/2 (terminal half-life of the analyte in plasma)(up to 168 hours after administration)
研究者
相似试验
已完成
1 期
Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female SubjectsHealthyNCT02183636Boehringer Ingelheim39
已完成
1 期
Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese VolunteersHealthyNCT02102932Boehringer Ingelheim96
已完成
1 期
Phase 1 Bioavailability Study of SYR-322METHealthy VolunteersNCT02508168Takeda24
已完成
1 期
A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution FormulationType 2 Diabetes Mellitus (T2DM)NCT02672839Ligand Pharmaceuticals12
已完成
1 期
A Study to Determine the Relative Oral Bioavailability of Single Dose Administration of TMC207, Under Fed and Fasted Conditions in Healthy ParticipantsHealthyNCT00946842Tibotec BVBA28